A CNN report reveals serious flaws in the FDA's AI tool, Elsa. Sources say Elsa has fabricated studies, misrepresented existing research, and lacks access to necessary documents. This raises concerns about the reliability of AI in regulatory processes and the potential impact on public health decisions. The report highlights a significant setback for the FDA's efforts to integrate AI into its review processes, questioning the current capabilities and oversight of such technologies within the agency. The findings suggest a need for more rigorous testing and validation before deploying AI tools in critical regulatory functions.